Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Phase 1 Study of KHK2455 in Combination With Avelumab in Adult Subjects With Locally Advanced or Metastatic Urothelial Carcinoma

Trial Profile

An Open-label, Phase 1 Study of KHK2455 in Combination With Avelumab in Adult Subjects With Locally Advanced or Metastatic Urothelial Carcinoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary) ; KHK 2455 (Primary)
  • Indications Carcinoma; Urogenital cancer
  • Focus Adverse reactions; Proof of concept
  • Sponsors Kyowa Kirin Pharmaceutical Development
  • Most Recent Events

    • 27 Sep 2019 Planned End Date changed from 25 May 2021 to 25 Feb 2022.
    • 27 Sep 2019 Planned primary completion date changed from 31 Mar 2021 to 31 Dec 2021.
    • 13 Aug 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 15 Apr 2019 to 30 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top